VANDA PHARMACEUTICALS INC. Deferred Foreign Income Tax Expense (Benefit)
VANDA PHARMACEUTICALS INC. (VNDA) reported Deferred Foreign Income Tax Expense (Benefit) of $38.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-12
- VANDA PHARMACEUTICALS INC. deferred foreign income tax expense (benefit) for fiscal 2025 was $38.00K.
- VANDA PHARMACEUTICALS INC. deferred foreign income tax expense (benefit) for fiscal 2024 was -$3.00K.
- VANDA PHARMACEUTICALS INC. deferred foreign income tax expense (benefit) for fiscal 2023 was -$15.00K, a 600.00% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. deferred foreign income tax expense (benefit) for fiscal 2022 was $3.00K, a 86.36% decline from fiscal 2021.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $38.00K 10-K · filed 2026-02-12 |
| 2024-12-31 | -$3.00K 10-K · filed 2026-02-12 |
| 2023-12-31 | -$15.00K 10-K · filed 2026-02-12 |
| 2022-12-31 | $3.00K 10-K · filed 2025-02-14 |
| 2021-12-31 | $22.00K 10-K · filed 2024-02-08 |
| 2020-12-31 | -$42.00K 10-K · filed 2023-02-09 |
| 2019-12-31 | -$16.00K 10-K · filed 2022-02-24 |
| 2018-12-31 | -$14.00K 10-K · filed 2021-02-11 |
| 2017-12-31 | $137.00K 10-K · filed 2020-02-26 |
| 2016-12-31 | -$104.00K 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |